Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9: a promising therapeutic target for dyslipidemias?

Trends in endocrinology and metabolism: TEM - 1 Apr 2006

Lambert Gilles, Krempf Michel, Costet Philippe

Abstract excerpt

PCSK9 is the third gene to be implicated in autosomal dominant hypercholesterolemia. The recent discovery of mutations in PCSK9 protein associated with low plasma low-density lipoprotein in humans, the characterization of PCSK9-deficient mice hypersensitive to statins and the severely pathological phenotype of D374Y PCSK9-mutated patients shed a new light on this gene: is it a promising therapeutic target for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors
Share to Hypercholesterolemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperlipidemias

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Receptors, LDL

Share to Serine Endopeptidases

Source

Identifiers

PMID: 16487721
DOI: 10.1016/j.tem.2006.02.001

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9: a promising therapeutic target for dyslipidemias?PMID 16487721Read ↗

PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.Semantic proximity Read ↗

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.Semantic proximity Read ↗

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisSemantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

The PCSK9 decade.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.